Literature DB >> 21939724

Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.

Angela Domínguez1, Pilar Ciruela, Juan José García-García, Fernando Moraga, Mariona F de Sevilla, Laura Selva, Francis Coll, Carmen Muñoz-Almagro, Ana María Planes, Gemma Codina, Iolanda Jordán, Cristina Esteva, Sergi Hernández, Núria Soldevila, Neus Cardeñosa, Joan Batalla, Luis Salleras.   

Abstract

The aim of this study was to evaluate the effectiveness of the administration of the 7-valent pneumococcal conjugate vaccine in a region with an intermediate vaccination coverage. A matched case-control study was carried out in children aged 7-59 months with invasive pneumococcal disease (IPD) admitted to two university hospitals in Catalonia. Three controls matched for hospital, age, sex, date of hospitalization and underlying disease were selected for each case. Information on the vaccination status of cases and controls was obtained from the vaccination card, the child's health card, the hospital medical record or the vaccination register of the primary healthcare center where the child was attended for non-severe conditions. A conditional logistic regression analysis was made to control for the effect of possible confounding variables. The adjusted vaccination effectiveness of the complete vaccination schedule (3 doses at 2, 4 and 6 months and a fourth dose at 15 months, 2 doses at least two months apart in children aged 12-23 months or a single dose in children aged >24 months) in preventing IPD caused by vaccine serotypes was 93.7% (95% CI 51.8-99.2). It was not effective in preventing cases caused by non-vaccine serotypes. The results of this study carried out in a population with intermediate vaccination coverage confirm those of other observational studies showing high levels of effectiveness of routine 7-valent pneumococcal conjugate vaccination.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21939724     DOI: 10.1016/j.vaccine.2011.09.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Are risk factors associated with invasive pneumococcal disease according to different serotypes?

Authors:  Pilar Ciruela; Núria Soldevila; Laura Selva; Sergi Hernández; Juan Jose Garcia-Garcia; Fernando Moraga; Mariona F de Sevilla; Gemma Codina; Ana Maria Planes; Cristina Esteva; Francis Coll; Neus Cardeñosa; Iolanda Jordan; Joan Batalla; Luis Salleras; Carmen Muñoz-Almagro; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

2.  Epidemiology of vaccine-preventable invasive diseases in Catalonia in the era of conjugate vaccines.

Authors:  Pilar Ciruela; Ana Martínez; Conchita Izquierdo; Sergi Hernández; Sonia Broner; Carmen Muñoz-Almagro; Àngela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2013-01-09       Impact factor: 3.452

Review 3.  Impact of pneumococcal conjugate vaccination on otitis media: a systematic review.

Authors:  Sylvia Taylor; Paola Marchisio; Anne Vergison; Julie Harriague; William P Hausdorff; Mark Haggard
Journal:  Clin Infect Dis       Date:  2012-03-15       Impact factor: 9.079

4.  Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.

Authors:  Ángela Domínguez; Pilar Ciruela; Sergi Hernández; Juan José García-García; Núria Soldevila; Conchita Izquierdo; Fernando Moraga-Llop; Alvaro Díaz; Mariona F de Sevilla; Sebastià González-Peris; Magda Campins; Sonia Uriona; Johanna Martínez-Osorio; Anna Solé-Ribalta; Gemma Codina; Cristina Esteva; Ana María Planes; Carmen Muñoz-Almagro; Luis Salleras
Journal:  PLoS One       Date:  2017-08-14       Impact factor: 3.240

Review 5.  Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls.

Authors:  Jennifer R Verani; Abdullah H Baqui; Claire V Broome; Thomas Cherian; Cheryl Cohen; Jennifer L Farrar; Daniel R Feikin; Michelle J Groome; Rana A Hajjeh; Hope L Johnson; Shabir A Madhi; Kim Mulholland; Katherine L O'Brien; Umesh D Parashar; Manish M Patel; Laura C Rodrigues; Mathuram Santosham; J Anthony Scott; Peter G Smith; Halvor Sommerfelt; Jacqueline E Tate; J Chris Victor; Cynthia G Whitney; Anita K Zaidi; Elizabeth R Zell
Journal:  Vaccine       Date:  2017-04-22       Impact factor: 3.641

6.  A systematic literature review and network meta-analysis feasibility study to assess the comparative efficacy and comparative effectiveness of pneumococcal conjugate vaccines.

Authors:  Ashleigh McGirr; Shehzad M Iqbal; Patricia Izurieta; Carla Talarico; Janneke Luijken; Josefine Redig; Rachel S Newson
Journal:  Hum Vaccin Immunother       Date:  2019-06-19       Impact factor: 3.452

Review 7.  Case-control vaccine effectiveness studies: Data collection, analysis and reporting results.

Authors:  Jennifer R Verani; Abdullah H Baqui; Claire V Broome; Thomas Cherian; Cheryl Cohen; Jennifer L Farrar; Daniel R Feikin; Michelle J Groome; Rana A Hajjeh; Hope L Johnson; Shabir A Madhi; Kim Mulholland; Katherine L O'Brien; Umesh D Parashar; Manish M Patel; Laura C Rodrigues; Mathuram Santosham; J Anthony Scott; Peter G Smith; Halvor Sommerfelt; Jacqueline E Tate; J Chris Victor; Cynthia G Whitney; Anita K Zaidi; Elizabeth R Zell
Journal:  Vaccine       Date:  2017-04-23       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.